Rituximab-induced diffuse ischemic colitis: A case report
Surgical Pathology Department, Santo Spirito Hospital, Viale Giolitti 2, Casale Monferrato, Italy.
Case Study
GSC Biological and Pharmaceutical Sciences, 2021, 14(02), 051-052.
Article DOI: 10.30574/gscbps.2021.14.2.0036
Publication history:
Received on 25 January 2021; revised on 02 Februay 2021; accepted on 04 Februay 2021
Abstract:
In the present manuscript a case of a 61 years old man with a form of unclear colitis is reported. The patient presented to our hospital with history of prolonged diarrhea and consequent profound dehydration after treatment with an immunotherapeutic cycle with Rituximab for a B cell lymphoma. An endoscopic pan-colonic examination was performed and some intestinal randomized biopsies were done as to confirm the clinic hypothesis of a colitis, as to define its etiopathogenesis. Histopathological picture of the colon biopsy fragments suggested a diffuse colitis with ischemic aspects. Herein the involvement of rituximab in determining pancolitis is discussed.
Keywords:
Rituximab; Pancolitis; Colon biopsy; Mucosal ischemia; Adverse reaction
Full text article in PDF:
Copyright information:
Copyright © 2021 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
